plerixafor has been researched along with Congenital Immunodeficiency Disease in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Shoshan, M; Jfri, A; Litvinov, IV; Merati, N; Popradi, G; Sivachandran, S; Vinh, DC | 1 |
| Chen, H; Poznansky, MC; Tannous, BA; Wang, J | 1 |
| Aknin, ML; Bachelerie, F; Balabanian, K; Bertrand, Y; Calmette, J; Donadieu, J; Evrard, M; Gallego, C; Lefrançois, M; Marin-Esteban, V; Mercier-Nomé, F; Ng, LG; Pionnier, N; Roriz, M; Schlecht-Louf, G; Suarez, F; Vétillard, M | 1 |
| De Filippo, K; Rankin, SM | 1 |
| Bianchi, DA; Blair, EA; Buck, CB; Calvo, KR; Cho, E; Gardner, PJ; Landon, EM; Liu, Q; McDermott, DH; Murphy, PM; Neves, JF; Pastrana, DV; Pittaluga, S; Silva, SL; Trout, HH; Velez, D | 1 |
| Al Ustwani, O; Kurzrock, R; Wetzler, M | 1 |
| Anaya-O'Brien, S; Calvo, KR; Cowen, EW; DeCastro, R; Evbuomwan, MO; Fleisher, TA; Giuntoli, RL; Grimes, GJ; Hilligoss, D; Hwang, ST; Kuhns, DB; Kwatemaa, N; Littel, P; Liu, Q; Lopez, L; Malech, HL; Marquesen, MM; McDermott, DH; Merideth, MA; Murphy, PM; Pittaluga, S; Priel, DA; Starling, J; Stratton, P; Ulrick, J; Velez, D | 1 |
| Broxmeyer, HE | 1 |
| Anaya-O'Brien, S; Chen, H; DeCastro, R; Deng, F; Garofalo, M; Hilligoss, D; Kelly, C; Kwatemaa, N; Liu, Q; Lopez, J; Malech, HL; Marquesen, M; McDermott, DH; Murphy, PM; Ojode, T; Ulrick, J | 1 |
| Badolato, R; Dotta, L; Tassone, L | 1 |
| Aprikyan, A; Bolyard, AA; Dale, DC; Hsu, FJ; Kelley, ML; Makaryan, V; Westrup, EC; Wood, B | 1 |
| Anaya-O'Brien, S; Decastro, R; Filho, JO; Fleisher, TA; Garofalo, M; Hilligoss, D; Kelly, C; Kuhns, DB; Kwatemaa, N; Littel, P; Liu, Q; Malech, HL; Marquesen, MM; McDermott, DH; Murphy, PM; Penzak, SR; Priel, DA; Ulrick, J | 1 |
| Diaz, GA | 1 |
5 review(s) available for plerixafor and Congenital Immunodeficiency Disease
| Article | Year |
|---|---|
Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Topics: Agammaglobulinemia; Benzylamines; Cyclams; Fantasy; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Neutropenia; Papillomavirus Infections; Primary Immunodeficiency Diseases; Receptors, CXCR4; Syndrome; Warts | 2022 |
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Benzylamines; Cyclams; Drug Contamination; HIV Infections; Humans; Neoplasms; Primary Immunodeficiency Diseases; Receptors, CXCR4; Signal Transduction; Tumor Microenvironment; Warts | 2020 |
CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease.
Topics: Animals; Benzylamines; Bone Marrow; Cell Survival; Chemokine CXCL12; Cyclams; Hematologic Agents; Heterocyclic Compounds; HMGB1 Protein; Homeostasis; Humans; Imidazoles; Immunologic Deficiency Syndromes; Inflammation; Mice; Mutation; Neutrophils; Peptide Fragments; Primary Immunodeficiency Diseases; Receptors, CXCR4; Serum Albumin; Spleen; Warts | 2018 |
Genetics on a WHIM.
Topics: Animals; Benzylamines; Cyclams; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Primary Immunodeficiency Diseases; Receptors, CXCR4; Warts | 2014 |
Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
Topics: Agammaglobulinemia; Anti-Bacterial Agents; Bacterial Infections; Benzylamines; Bone Marrow; Chemokine CXCL12; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Lymphopenia; Male; Mutation; Neutropenia; Neutrophils; Primary Immunodeficiency Diseases; Receptors, CXCR4; Signal Transduction; Warts | 2011 |
3 trial(s) available for plerixafor and Congenital Immunodeficiency Disease
| Article | Year |
|---|---|
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
Topics: Adult; Benzylamines; Cyclams; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Male; Middle Aged; Primary Immunodeficiency Diseases; Receptors, CXCR4; Time Factors; Warts | 2014 |
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Bone Marrow Diseases; Cyclams; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Precursor Cells; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Leukopenia; Male; Middle Aged; Primary Immunodeficiency Diseases; Receptors, CXCR4; Warts | 2011 |
The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Benzylamines; Blood Cell Count; Cyclams; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Leukocytes; Lymphopenia; Male; Middle Aged; Primary Immunodeficiency Diseases; Receptors, CXCR4; Treatment Outcome; Warts; Young Adult | 2011 |
5 other study(ies) available for plerixafor and Congenital Immunodeficiency Disease
| Article | Year |
|---|---|
CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation.
Topics: Alphapapillomavirus; Animals; Benzylamines; Cell Count; Cell Differentiation; Chemokine CXCL12; Chemotaxis; Cyclams; Dendritic Cells; Epidermis; Female; Gene Knock-In Techniques; Genes, Viral; Humans; Inflammation; Langerhans Cells; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Transgenic; Organ Specificity; Parabiosis; Primary Immunodeficiency Diseases; Receptors, CXCR4; Recombinant Proteins; Warts | 2021 |
Plerixafor for the Treatment of WHIM Syndrome.
Topics: Benzylamines; Bone Marrow; Bone Marrow Examination; Cyclams; Fatal Outcome; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Male; Middle Aged; Neoplasms, Squamous Cell; Phenotype; Primary Immunodeficiency Diseases; Primary Myelofibrosis; Receptors, CXCR4; Warts | 2019 |
A WHIM satisfactorily addressed.
Topics: Benzylamines; Cyclams; Female; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Male; Primary Immunodeficiency Diseases; Receptors, CXCR4; Warts | 2014 |
AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
Topics: Adult; Animals; Benzylamines; CHO Cells; Cricetinae; Cyclams; Female; Flow Cytometry; Gene Expression Regulation; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; K562 Cells; Primary Immunodeficiency Diseases; Receptors, CXCR4; Warts | 2011 |
Released on a WHIM.
Topics: Benzylamines; Cyclams; Female; Granulocyte Precursor Cells; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Lymphopenia; Male; Primary Immunodeficiency Diseases; Warts | 2011 |